Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2007-08-21
2007-08-21
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S085600, C424S143100
Reexamination Certificate
active
10607598
ABSTRACT:
A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5620686 (1997-04-01), Mason
patent: 5693762 (1997-12-01), Queen et al.
patent: 5817306 (1998-10-01), Haskill et al.
patent: 6013256 (2000-01-01), Light et al.
patent: 6096728 (2000-08-01), Collins et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6346247 (2002-02-01), Stafford et al.
patent: WO89/09622 (1989-10-01), None
patent: WO90/07861 (1990-07-01), None
patent: WO92/13886 (1992-08-01), None
patent: WO93/01289 (1993-01-01), None
patent: WO 00/25816 (2000-05-01), None
Goodin, Therepeutic developments in multiple sclerosis (2000), Exp. Opin. Invest. Drugs, vol. 9(4), pp. 655-670.
“Advances in Basic and Clinical Research on MS Reported at AAN,” www.nationalmssociety.org/Research-2003Apr15.asp, Apr. 15, 2003.
Bellamy et al., “The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes,”Clin. Exp. Immunol.61: 248-256, 1985.
Brown et al., “Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival,”Proc. Natl. Acad. Sci. USA88: 2663-2667, 1991.
Church, A., “Clinical advances in therapies targeting the interleukin-2 receptor,”Q J Med96: 91-102, 2003.
Giorelli et al., “IFN-β1a Modulates the Expression of CTLA-4 and CD28 Splice Variants in Human Mononuclear Cells: Induction of Soluble Isoforms,”Journal of Interferon and Cytokine Research21: 809-812, 2001.
Junghans et al., “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders,”Cancer Res. 50(5): 1495-1502, 1990.
Khoury et al., “Changes in Activated T Cells in the Blood Correlate with Disease Activity in Multiple Sclerosis,”Arch. Neurol57: 1183-1189, 2000.
Lee et al., “Spatial mapping of T2and gadolinium-enhancing T1lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?”Brain122: 1261-1270, 1999.
Lehky et al., “Reduction in HTLV-I Proviral Load and Spontaneous Lymphoproliferation in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis Patients Treated with Humanized Anti-Tac,”Annals of Neurology44: 942-947, 1998.
Marwick, C., “Scientists Recall Progress and Promise of Translational Research,”J. Natl. Cancer Inst. 93: 13-15, 2001.
“Monoclonal antibodies with clinical indications,” www/imgt.cines.fr:8104/textes/IMGTrepertoire/GenesClinical/monoclonalantibodies, May 19, 2003.
Nussenblatt et al., “Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial,”Proc. Natl. Acad. Sci. USA96 (13): 7462-7466, 1999.
Package insert for Rebif (interferon beta-1a), Nov. 6, 2002.
Package insert for Zenapax (Daclizumab), Dec. 1997.
Paty et al., “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis,”Neurology43:662-667.
Posey et al., “TCP presents its annual list of drugs in development and what their approval will mean to long-term care patients,” www.ascp.com/public/pubs/tcp/1997/apr
ewdrugs.html, Jun. 4, 2002.
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,”Proc. Natl. Acad. Sci. USA86 (24): 10029-10033, 1989.
Samkoff, Lawrence, “Multiple Sclerosis: Update of Treatment,”Hospital Physicianpp. 21-27, 2002.
“Study of Zenapax in the treatment of multiple sclerosis,” www.mult.sclerosis.org
ews/Nov2000/ZenapaxMS.html, Nov. 27, 2000.
Waldmann, et al., “Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy,”Hematology(1): 394, 2000.
Wandinger et al., “Complex Immunomodulatory Effects of Interferon-beta in Multiple Sclerosis Include the Upregulation of T Helper 1-associated Marker Genes,”Ann. Neurol., 50(3):349-57 (2001).
Nussenblatt et al.,Proc. Natl. Acad. Sci. USA, 96:7462-7466, 1999.
Patti et al.,Acta Neurol. Scand., 100:283-289, 1999.
Becker et al. “Differential Gene Expression in Multiple Sclerosis Lesions Identified Using cDNA Microarrays,”Poster Abstracts / J. Neuroimmunology90:71 (1998)Abstract only.
Sharief et al. “Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-β therapy,”J. Neuroimmunology129:224-231 (2002).
Bielekova et al., “Daclizumab Inhibits Inflammation and Stabilizes Disease Progression in MS,”Short Communication—Annals of Neurology, 17 pages, Aug. 14, 2006.
Bielekova et al., “Humanized anti-CD25 (daclizumab) inihibits disease activity in multiple sclerosis patients failing to respond to interferon {beta},”PNAS101(23):8705-8708 (Jun. 8, 2004).
Bielekova et al., “Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R {alpha}-targeted therapy (daclizumab) in multiple sclerosis,”PNAS103(15):5941-5946 (Apr. 11, 2006).
Rose et al., “Treatment of Multiple Sclerosis with an Anti-Interleukin-2 Receptor Monoclonal Antibody,”Ann Neurol56:864-867 (2004).
Paty et al., “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis,”Neurology43:662-667, 1993.
Bielekova Bibiana
Martin Roland
McFarland Henry
Klarquist & Sparkman, LLP
Saoud Christine J.
Seharaseyon Jegatheesan
The United States of America as represented by the Secretary of
LandOfFree
Method for the treatment of multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of multiple sclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3868249